Curated Wealth Partners LLC Sells 35,373 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Curated Wealth Partners LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 96.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,365 shares of the biopharmaceutical company’s stock after selling 35,373 shares during the period. Curated Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $1,035,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. Bank of New York Mellon Corp bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $472,950,000. Deutsche Bank AG acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Finally, Man Group plc acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $272,460,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on REGN. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Raymond James Financial boosted their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Finally, Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $845.21.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
• Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
• Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
• Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
• Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
• Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $796.34 on Friday. The stock’s 50 day moving average is $791.59 and its 200 day moving average is $721.30. Regeneron Pharmaceuticals, Inc. has a one year low of $564.00 and a one year high of $859.34. The firm has a market cap of $81.99 billion, a P/E ratio of 19.68, a P/E/G ratio of 1.35 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the business earned $12.81 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 in the last three months. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.